Peptides and the detoxification conversation — what's real and what's marketing

The reason this narrative sticks is that it's not entirely wrong. It's approximately thirty percent correct biology dressed up in marketing that fills in the remaining seventy percent with confident imprecision.

The body does detoxify. Continuously, automatically, and with sophisticated machinery that has been evolving for several hundred million years. Understanding how that machinery actually works is the starting point for separating legitimate concerns about environmental burden from the claims that don't hold up.

The liver is the primary detoxification organ, and it operates through a two-phase system that is genuinely important and worth knowing. Phase I detoxification involves the cytochrome P450 enzyme family — a collection of roughly fifty enzymes that perform oxidation, reduction, and hydrolysis reactions on toxins, drugs, hormones, and other fat-soluble compounds. The goal of Phase I is to make these compounds more reactive and more water-soluble, so they can then be processed in Phase II. This is not neutralization — Phase I metabolites are sometimes more reactive than the parent compound. Phase I metabolite accumulation without adequate Phase II processing is where problems can occur.

Phase II — conjugation — attaches polar molecules to the Phase I metabolites, making them water-soluble enough for excretion. The major Phase II pathways are glutathionylation (attachment of glutathione), glucuronidation (attachment of glucuronic acid), sulfation, methylation, and acetylation. Glutathionylation is quantitatively the most important: glutathione is the liver's primary endogenous antioxidant and a central Phase II conjugate, and its availability is often rate-limiting for Phase II throughput. The kidneys then filter water-soluble Phase II conjugates out of the blood and excrete them in urine. The intestine handles bile-conjugated compounds, excreted into the gut for fecal elimination. Lymphatic clearance moves larger molecules, cellular debris, and fat-soluble compounds that don't enter the portal circulation directly. The skin eliminates some compounds through sweating, though its quantitative contribution to overall detoxification is modest relative to the liver-kidney axis.

This system works. For most people most of the time, it processes an enormous load of endogenous metabolites — hormones, inflammatory mediators, cellular waste — plus exogenous substances including medications, food additives, and environmental exposures. The marketing framing that this system is perpetually overwhelmed and requires external support for ordinary modern living is not supported by evidence. The framing that it can be meaningfully burdened by specific, measurable exposures under specific circumstances is.

The legitimate concerns in environmental medicine are specific. Heavy metals — lead, mercury, inorganic arsenic, cadmium — are real exposures with real health effects. Lead exposure is more common than most people assume: old paint in housing built before 1978, some imported consumer goods, certain occupational settings. Mercury accumulates in large, long-lived fish (tuna, swordfish, king mackerel, tilefish) and in dental amalgam, and in people with high fish consumption or amalgam burden it can reach levels associated with subclinical neurological effects. Arsenic is present in some groundwater systems, notably in private wells in certain regions. Cadmium accumulates in the kidneys with prolonged low-level exposure from contaminated soil and some foods, and cigarette smoke is a significant cadmium source. These are not theoretical concerns — blood and urine testing can quantify them, and clinical chelation protocols exist for people with confirmed heavy metal toxicity.

Persistent organic pollutants — PCBs, dioxins, organochlorine pesticides — accumulate in adipose tissue because they're highly fat-soluble and the body has limited capacity to eliminate them. The relevant exposures are often historical (many were banned decades ago) but persist in the environment and food chain, particularly in fatty animal products. Mold biotoxin exposure in water-damaged buildings — particularly mycotoxins produced by Stachybotrys and Aspergillus species — represents a legitimate exposure concern for people in genuinely affected environments, with a developing evidence base for effects on cognition, immune function, and inflammatory burden. Alcohol is the most common intentional metabolic burden on the liver, and its Phase I metabolism via alcohol dehydrogenase and CYP2E1 produces acetaldehyde — a genuinely toxic intermediate — before Phase II processes it further. Medication burden, particularly in people on polypharmacy, can strain the same CYP450 pathways that handle other compounds.

These are the situations where thinking about detoxification is medically legitimate. The testing is specific: blood and urine heavy metal panels for metal exposure, organic acid testing for some environmental toxins, mycotoxin urine testing in appropriate building-exposure contexts. The interventions are also specific and — in cases of genuine toxicity — involve evidence-based medical chelation rather than supplement protocols.

Now to the peptides and related compounds that have real biology relevant to these detoxification mechanisms.

Glutathione is not technically a peptide in the research-compound sense — it's a tripeptide naturally produced by the body, and it's the body's most abundant endogenous antioxidant. Its relevance to detoxification is not speculative: glutathione is the primary Phase II conjugate in the liver, directly required for the elimination of oxidative stress byproducts, heavy metal complexes, and a range of reactive intermediates. Glutathione depletion is a documented feature of acetaminophen toxicity, heavy metal exposure, and chronic alcohol use. Intravenous glutathione administration has evidence for specific clinical contexts, and N-acetylcysteine — a glutathione precursor — is the standard treatment for acetaminophen overdose precisely because it restores hepatic glutathione. Oral glutathione bioavailability is historically debated, though liposomal formulations have better absorption data. The glutathione story is one of real biology, real evidence in specific contexts, and considerable marketing hyperbole around general "detox" use.

NAD+ (and its precursors, NMN and NR) is relevant to detoxification machinery through mitochondrial energy support rather than direct conjugation. Phase I and Phase II enzyme systems require cellular energy — they're metabolically expensive. Mitochondrial efficiency, supported by NAD+, underlies the liver's capacity to process its metabolic load. Research on NAD+ has focused on its roles in cellular energy metabolism, DNA repair, and sirtuin activation, which has relevance to hepatocyte function. The NAD+ connection to detoxification is one step removed from the direct mechanisms — it's about the energy available for the machinery, not the machinery itself — but the biology is real.

Ovagen is a peptide bioregulator from the Khavinson tradition — the Russian peptide bioregulator research program that has developed short peptides as organ-specific bioregulators. Ovagen is researched as a liver bioregulator, with the hypothesis that it supports hepatocyte function and liver tissue maintenance in the way that Khavinson peptides are generally theorized to support their target organs through epigenetic mechanisms. The Khavinson peptide research exists primarily in Russian literature, with limited Western replication, and the evidence base for Ovagen specifically in liver support is preliminary and not established by controlled trials in Western clinical frameworks.

BPC-157, researched primarily in gut and healing contexts, has relevance to the detoxification conversation through a specific mechanism: gut barrier integrity. Intestinal permeability — the "leaky gut" phenomenon — is real in the sense that increased paracellular permeability allows microbial products and other intestinal contents to enter the portal circulation, increasing the liver's burden and contributing to systemic inflammatory activation. Research on BPC-157 in gut models has explored its effects on tight junction integrity and intestinal epithelial protection. Whether this translates to meaningful improvement in intestinal elimination or reduction in hepatic inflammatory burden in humans with specific GI dysfunction is not established, but the mechanistic pathway is coherent.

The critical reframe here is the direction of thinking. Exposure reduction is the highest-evidence intervention available for environmental toxin burden. Reducing blood lead levels requires identifying and eliminating the source; no supplement accelerates lead clearance in ways that approach the effectiveness of removing the exposure. Reducing mercury requires modifying fish consumption and, in clinical toxicity, medical chelation — not a liver cleanse. Supporting glutathione through nutrition (protein adequacy, sulfur-rich foods, adequate sleep) addresses the most important variable in Phase II capacity without requiring compounds at all. Weight-bearing exercise supports lymphatic flow. Adequate hydration supports renal excretion.

The "drainage" and "cleansing" protocol narrative is particularly worth examining critically because it often reverses the legitimate causal chain. The framing implies that symptoms are caused by toxin accumulation and that the compounds will remove the toxins, relieving the symptoms. The evidence for this chain in the absence of specific, measured toxic burden is absent. What is real is that metabolic stress — from alcohol, from medications, from genuine environmental exposures — can burden the Phase I/II system; that nutritional adequacy supports that system's function; and that specific compounds have evidence in specific clinical contexts. The gap between that and "you need a thirty-day detox protocol" is where marketing lives.

Environmental medicine — the specialty that takes heavy metal toxicity, mold-related illness, and chronic environmental exposure seriously — is the appropriate framework for people with genuine concerns about toxic burden. Testing comes before treatment. Identifying the specific exposure, quantifying it, and applying evidence-matched intervention is a different process from empiric supplement protocols sold on the premise of general toxin accumulation. If you have reason to believe you have a specific heavy metal or biotoxin exposure — occupational history, contaminated well water, a known water-damaged building — that concern deserves specific testing and evaluation by someone who thinks in those terms. What it doesn't require is a protocol designed to address an unspecified universal toxin load that hasn't been measured and may not exist.